Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
Author:
Funder
Universität Ulm
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Link
https://link.springer.com/content/pdf/10.1007/s40262-021-01095-x.pdf
Reference72 articles.
1. Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind Placebo-Controlled Trial. Adv Ther. 2019;36(6):1438–54. https://doi.org/10.1007/s12325-019-00943-4.
2. Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, Phase 3, Multicenter, Open-Label Study. Ther Apher Dial. 2020;24(2):115–25.
3. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Nephron. 2020;144(8):372–82. https://doi.org/10.1159/000508100.
4. Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: a randomized, double-blind, Phase 3 Trial. Clin J Am Soc Nephrol. 2020;15(8):1155–65. https://doi.org/10.2215/CJN.16011219.
5. Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Ther Apher Dial. 2021;25(5):575–85. https://doi.org/10.1111/1744-9987.13609.
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimizing the dosing regimen of roxadustat in kidney transplant recipients with early post-transplant anemia;Journal of Pharmaceutical Sciences;2024-09
2. Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence;Frontiers in Nephrology;2024-08-02
3. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction;Life Sciences;2024-06
4. Isoquinoline‐based intrinsic fluorescence assessment of erythropoiesis‐stimulating agent, Roxadustat (FG‐4592), in tablets: applications to content uniformity and human plasma evaluation;Luminescence;2024-04
5. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis;Renal Failure;2024-02-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3